Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth.

Ewing sarcoma is a rare but aggressive disease most common in young adults. This cancer is driven by a unique chimeric fusion oncogene but targeted strategies have been elusive. Here we report the identification of the protein kinase PKC-ß (PRKCB) as a disease-specific druggable target for treatment of Ewing sarcoma. We found that transcriptional activation of PRKCB was directly regulated by the chimeric fusion oncogene EWSR1-FLI1 that drives this cancer. PRKCB phosphorylated histone H3T6 to permit global maintenance of H3K4 trimethylation at a variety of gene promoters. PRKCB loss induced apoptosis in vitro and prevented tumor growth in vivo. Gene expression profiling revealed a strong overlap between genes modulated by EWSR1-FLI1 and PRKCB in regulating crucial signaling pathways. Taken together, our findings offer a preclinical proof-of-concept for PRKCB as a promising therapeutic target in Ewing sarcoma.

[1]  N. Munshi,et al.  Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). , 2006, Blood.

[2]  S. Lessnick,et al.  A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature , 2008, Cell cycle.

[3]  L. Moretti,et al.  Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation. , 2010, International journal of radiation oncology, biology, physics.

[4]  S. Lessnick,et al.  NR0B1 Is Required for the Oncogenic Phenotype Mediated by EWS/FLI in Ewing's Sarcoma , 2006, Molecular Cancer Research.

[5]  C. MacCarthy,et al.  Caveolin‐1 promotes resistance to chemotherapy‐induced apoptosis in Ewing's sarcoma cells by modulating PKCα phosphorylation , 2010, International journal of cancer.

[6]  I. Bièche,et al.  Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase Cβ Inhibitor Enzastaurin in Colon Cancer Cells , 2010, Molecular Cancer Therapeutics.

[7]  P. Lollini,et al.  Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. , 1996, Cancer research.

[8]  Toshifumi Ozaki,et al.  Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. , 2002, International journal of oncology.

[9]  R. Arceci.  Fusion Gene–Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma , 2010 .

[10]  R. Campbell,et al.  The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts , 2005 .

[11]  O. Delattre,et al.  Mesenchymal stem cell features of Ewing tumors. , 2007, Cancer cell.

[12]  Guy Perrière,et al.  Between-group analysis of microarray data , 2002, Bioinform..

[13]  A. Ashkenazi,et al.  TWEAK Induces Apoptosis through a Death-signaling Complex Comprising Receptor-interacting Protein 1 (RIP1), Fas-associated Death Domain (FADD), and Caspase-8 , 2011, The Journal of Biological Chemistry.

[14]  D. Loegering,et al.  Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy. , 2010, The Journal of biological chemistry.

[15]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[16]  Martin A. Koschat,et al.  Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. , 2001, Medical and pediatric oncology.

[17]  O. Delattre,et al.  The orphan nuclear receptor DAX1 is up‐regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors , 2006, International journal of cancer.

[18]  P. Meltzer,et al.  A Molecular Function Map of Ewing's Sarcoma , 2009, PloS one.

[19]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Lessnick,et al.  NR 0 B 1 Is Required for the Oncogenic Phenotype Mediated by EWS / FLI in Ewing ’ s Sarcoma , 2006 .

[21]  Andrew R. Gehrke,et al.  Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo , 2010, The EMBO journal.

[22]  T. Lawrence,et al.  Inhibition of Protein Kinase Cβ by Enzastaurin Enhances Radiation Cytotoxicity in Pancreatic Cancer , 2007, Clinical Cancer Research.

[23]  J. Ban,et al.  EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin , 2005, Oncogene.

[24]  Mark E. Davis,et al.  Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. , 2005, Cancer research.

[25]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[26]  A. Aurias,et al.  Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors. , 1984, Cancer genetics and cytogenetics.

[27]  Robin L. Jones,et al.  Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations , 2011, Sarcoma.

[28]  S. Lessnick,et al.  GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance , 2009, Oncogene.

[29]  Nicolò Riggi,et al.  EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. , 2010, Genes & development.

[30]  P. Meltzer,et al.  Gene expression profiling of human sarcomas: insights into sarcoma biology. , 2005, Cancer research.

[31]  M. Colombo,et al.  Xg expression in Ewing's sarcoma is of prognostic value and contributes to tumor invasiveness. , 2010, Cancer research.

[32]  O. Delattre,et al.  EWS/FLI-1 Silencing and Gene Profiling of Ewing Cells Reveal Downstream Oncogenic Pathways and a Crucial Role for Repression of Insulin-Like Growth Factor Binding Protein 3 , 2004, Molecular and Cellular Biology.

[33]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[34]  E. Barillot,et al.  The Oncogenic EWS-FLI1 Protein Binds In Vivo GGAA Microsatellite Sequences with Potential Transcriptional Activation Function , 2009, PloS one.

[35]  William Stafford Noble,et al.  Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project , 2007, Nature.

[36]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[37]  J. Slupsky,et al.  Vascular endothelial growth factor stimulates protein kinase CbetaII expression in chronic lymphocytic leukemia cells. , 2010, Blood.

[38]  B. Schmiedel,et al.  Membrane‐associated phospholipase A1 beta (LIPI) Is an Ewing tumour‐associated cancer/testis antigen , 2008, Pediatric blood & cancer.

[39]  Guy Perrière,et al.  MADE4: an R package for multivariate analysis of gene expression data , 2005, Bioinform..

[40]  Axel Imhof,et al.  Phosphorylation of histone H3T6 by PKCβI controls demethylation at histone H3K4 , 2010, Nature.

[41]  R. Myers,et al.  Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.

[42]  S. Treon,et al.  Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. , 2007, Blood.

[43]  M. Toyoda,et al.  EWS/ETS Regulates the Expression of the Dickkopf Family in Ewing Family Tumor Cells , 2009, PloS one.

[44]  T. Golub,et al.  Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. , 2006, Cancer cell.

[45]  S. Nelson,et al.  Detection of differentially expressed genes in primary tumor tissues using representational differences analysis coupled to microarray hybridization. , 1998, Nucleic acids research.

[46]  G. Sonpavde,et al.  Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine , 2009, Molecular Cancer Therapeutics.

[47]  Emmanuel Barillot,et al.  Beta‐catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics , 2009, The Journal of pathology.